-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although we already know that the high concentration of anti-biological drug antibodies will significantly increase the possibility of IBD patients receiving infliximab (IFX) treatment loss of response, but anti-infliximab (ATI) antibodies The high titer and low titer may have different clinical significance
.
The effect of ATI titer on the follow-up anti-TNF treatment effect has not been reported before
Although we already know that the high concentration of anti-biological drug antibodies will significantly increase the possibility of IBD patients receiving infliximab (IFX) treatment loss of response, but anti-infliximab (ATI) antibodies The high titer and low titer may have different clinical significance
To this end, the researchers conducted a multicenter retrospective cohort study for patients with IBD who were discontinued with infliximab due to high ATI titers and then switched to adalimumab
.
The Mayo score was used to evaluate the patient's disease activity, and the Esoterix assay was used to measure the IFX anti-drug antibody titer level
This study included a total of 90 IBD patients (69 CD, 17 UC, and 4 CD recurrence patients after ileal surgery)
.
The median antibody titers detected by Esoterix were similar in all patients (208 u/mL; p>0.
Figure: The impact of anti-drug antibody titer on subsequent treatment
This study confirmed that the presence of high titers of anti-infliximab (IFX) anti-drug antibodies does not predict that IBD patients will fail after receiving adalimumab treatment
.
.
Original source:
Alexa N.
High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
Leave a message here
